Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023.

Background: During the ongoing outbreak of clade II (MPXV), many U.S. patients were prescribed tecovirimat, an antiviral drug that was made available under an expanded access Investigational New Drug (EA-IND) program.

Safety of Antimicrobials for Postexposure Prophylaxis and Treatment of Anthrax: A Review.

Background: Bacillus anthracis, the causative agent for anthrax, poses a potential bioterrorism threat and is capable of causing mass morbidity and mortality. Antimicrobials are the mainstay of postexposure prophylaxis (PEP) and treatment of anthrax. We conducted this safety review of 24 select antimicrobials to identify any new or emerging serious or severe adverse events (AEs) to help inform their risk-benefit evaluation for anthrax.